PHIO PHARMACEUTICALS CORP

Phio Pharma Q2 2026 results: PH‑762 advances to clinical trial design, new equity round, and stronger board as R&D investments boost pipeline and liquidity.

Phio Pharmaceuticals launches commercial‑scale production of its cancer immunotherapy lead PH‑762, signaling readiness for U.S. launch and boosting investor prospects.

Phio Pharmaceuticals, a biotech firm focused on cancer immunotherapy, showcased at 2026 DealFlow Discovery and faces volatile stock yet promising asset value.

Phio Pharmaceuticals

Phio Pharmaceuticals: volatile stock, negative P/E, but steady progress in cancer immunotherapy research – can the biotech firm turn setbacks into breakthrough gains?

Phio Pharmaceuticals names David Deming lead independent director, boosting governance and investor confidence amid growing analyst coverage in biotech.

Phio Pharmaceuticals Corp is a biotechnology company dedicated to developing innovative cancer treatments and other healthcare solutions, with a focus on patient care and accessibility.

Phio Pharmaceuticals Corp’s stock has experienced significant volatility, with a 52-week high nearly ten times its current value, raising concerns about the company’s financial health and potential undervaluation.